Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real‐world experience from 1998 to 2015

Kim, Nathan G.; Nguyen, Pauline; Dang, Hansen; Kumari, Rita; García, Gabriel; Esquivel, Carlos O.; Nguyen, Mindie H.

doi:10.1002/cncr.31373

Cited by 38 publications

(40 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 21 ] Other studies also found that among HCC patients, Asian patients had higher survival rates although none have been able to discern a cause. [ 22 – 24 ]…”

Section: Discussionmentioning

confidence: 99%

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundEconomic burden of HBV and HCV infection are trending upwards.AimsCompare hepatitis B virus (HBV) and hepatitis C virus (HCV) related hospital admission rates, charges, mortality rates, causes of death in a US population-based study.MethodsRetrospective cohort analysis of HBV and HCV patients from the California Office of Statewide Health Planning and Development (2006–2013) database.ResultsA total of 23,891 HBV and 148,229 HCV patients were identified. Across the 8-year period, the mean increase for all-cause ($1,863 vs $1,388) and liver-related hospitalization charges ($1,175 vs $675) were significantly higher for the HBV cohort compared to the HCV cohort. HBV patients had significantly higher liver-related hospital charges per person per year than HCV patients after controlling for covariates ($123,239 vs $111,837; p = 0.002). Compared to HCV patients, adjusted mortality hazard ratio was slightly lower in HBV patients (relative risk = 0.96; 95% CI 0.94–0.99). The major causes and places of death were different. The three major causes of death for HBV were: other malignant neoplasms (35%), cardiovascular disease/other circulatory disorders (17%), and liver-related disease (15%) whereas for HCV patients were: liver-related disease (22%), other malignant neoplasms (20%), and cardiovascular disease (16%). Regarding the place of death, 53% of HBV patients and 44% of HCV patients died in hospital inpatient, respectively.ConclusionsHBV patients incurred higher liver-related hospital charges and higher mean increase for all-cause and liver-related hospitalization charges over the 8-year period compared to HCV patients. HBV patients had slightly lower mortality rate and their major causes and places of death were noticeably different from HCV patients.

show abstract

“…[ 21 ] Other studies also found that among HCC patients, Asian patients had higher survival rates although none have been able to discern a cause. [ 22 – 24 ]…”

Section: Discussionmentioning

confidence: 99%

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…An interesting finding from our study was that those of Asian ethnicity were over 70% less likely to die than those of non‐Asian ethnicity, although the country/region of residence was not significant. Although the reasons for this ethnic disparity remain unclear, it is a phenomenon that has long been described in several prior studies of the multiethnic U.S. population . One recent study analyzed 1,284 Asian and 7,072 non‐Hispanic white patients in a Surveillance, Epidemiology, and End Results Medicare‐linked database, 1994‐2011 .…”

Section: Discussionmentioning

confidence: 99%

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

Dang

Yeo

Yasuda³

et al. 2020

Hepatology

Self Cite

View full text Add to dashboard Cite

BaCKgRoUND aND aIMS:Survival data among patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) with interferon-free direct-acting antivirals (DAAs) in both Asian and western countries are limited. Survival rates were compared between patients with HCV-related HCC who were untreated for HCV and those who achieved SVR. appRoaCH aND ReSUltS: Using data from two U.S. and six Asian centers from 2005 to 2017, we categorized 1,676 patients who were mono-infected with HCV-related HCC into patients untreated for HCV (untreated group) and DAA-treated patients with SVR (SVR group) and matched by propensity score matching (PSM); multivariable Cox regression with HCV treatment status as a time-varying covariate was used to determine mortality risk and landmark analysis to avoid immortal time bias. There were 1,239 untreated patients and 437 patients with SVR. After PSM, background risks of the 321 pairs of matched patients were balanced (all P > 0.05). After time-varying adjustment for HCV treatment initiation compared with untreated patients, patients with SVR had significantly higher 5-year overall survival (87.78% vs. 66.05%, P < 0.001). Multivariable Cox regression showed that SVR was independently associated with a 63% lower risk of 5-year all-cause mortality (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.16-0.83; P = 0.016) and 66% lower risk of 5-year liver-related mortality (HR, 0.34; 95% CI, 0.13-0.88; P = 0.026) with similar trends after removing patients with liver transplants. Landmark analysis at 90, 180, and 360 days showed consistent results (HRs ranged 0.22 to 0.44, all P < 0.05). CoNClUSIoN:In this multinational consortium, patients with HCV-related HCC who obtained SVR achieved a 60%-70% improvement in 5-year survival (both all-cause and liver related) compared with patients untreated for HCV. Patients eligible for HCC therapy should also be considered for DAA therapy.

show abstract

“…The mortality rate of hepatocellular carcinoma (HCC) ranks the third among malignant tumors in the world, with about 1 million new cases diagnosed each year, and the incidence rate of HCC continues to rise [1,2]. Due to the late diagnosis, drug resistance, tumor recurrence and metastasis, etc., the 5-year overall survival (OS) rate of HCC is low of approximately 7% [3,4].…”

Section: Introductionmentioning

confidence: 99%

MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7

et al. 2020

View full text Add to dashboard Cite

Objective This study aims to explore the mechanism of the miR-424-5p/E2F7 axis in hepatocellular carcinoma (HCC) and provide new ideas for targeted therapy of HCC. Methods Bioinformatics analysis was used to identify the target differentially expressed miRNA in HCC and predict its target gene. qRT-PCR was employed to verify the expression of miR-424-5p and E2F7 mRNA in HCC cells. Western blot was performed to detect the effect of miR-424-5p ectopic expression on the protein expression of E2F7. CCK-8 was used to detect proliferative activity of HCC cells and flow cytometry was carried out for analyzing cell cycle distribution. Dual luciferase reporter assay was conducted to verify the direct targeting relationship between miR-424-5p and E2F7. Results We observed that miR-424-5p was down-regulated in HCC cells. CCK-8 showed that overexpression of miR-424-5p inhibited cell proliferation, and flow cytometry showed that miR-424-5p could block cells in G0/G1 phase. E2F7 was up-regulated in HCC cells, and E2F7 overexpression could facilitate the proliferative ability of HCC cells and promote the cell cycle progressing from G0/G1 to S phase. Furthermore, dual-luciferase reporter assay indicated that miR-424-5p could directly down-regulate E2F7 expression. Analysis on cell function demonstrated that miR-424-5p inhibited the proliferation of HCC cells and blocked cell cycle at G0/G1 phase by targeting E2F7. Conclusion Our results proved that E2F7 was a direct target of miR-424-5p, and miR-424-5p could regulate cell cycle and further inhibit the proliferation of HCC cells by targeting E2F7.

show abstract

Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real‐world experience from 1998 to 2015

Cited by 38 publications

References 40 publications

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7

Contact Info

Product

Resources

About